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Abstract 
Background: Growing evidence suggests a pathophysiological role of cytokines in post-
traumatic stress disorder (PTSD). Tumor necrosis factor (TNF)-α is a key cytokine. Therefore, 
we performed a systematic review to examine the findings regarding TNF- derived from both 
animal and human studies of PTSD.  
Methods: Using PRISMA guidelines, we reviewed relevant articles in PubMed from inception 
until 11th April 2017. Human studies that reported group comparisons and/or longitudinal 
investigations of TNF-α production/concentration were included. Research reporting on TNF-
α levels in animal models of PTSD were also included. 
Results: Twenty-seven articles were identified. Data from human cross-sectional studies 
suggests that plasma/serum levels of TNF-α are elevated in those with PTSD, as compared to 
healthy controls. Longitudinal assessments of TNF-α are limited and data are mixed. Limited 
data from animal studies suggest an increased TNF-α production in the hippocampus of rats 
following stress, which can be reversed by immunomodulatory drugs.  
Conclusions: Our findings suggest TNF-α may be a potential biomarker and treatment target 
for PTSD. Findings need to be considered in light of heterogeneous methods for 
measurement and analysis of TNF-α concentration. Longitudinal research is needed to 
understand the role of TNF-α in the development and/or maintenance of PTSD. 
 
Key Words: Cytokines, Tumor necrosis factor (TNF)-alpha, Post-traumatic stress disorder, 
Biomarker, Immunomodulatory drugs, Cytokines 
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Introduction  
Post-traumatic stress disorder (PTSD) is a mental disorder, which may develop following an 
exposure to traumatic events, such as war, catastrophic accidents, and instances of violence. 
According to the International Classification of Diseases (ICD)-10, the specific criteria for 
diagnosis include (i) the exposure to a stressful event or situation of exceptionally threatening 
or catastrophic nature; (ii) a persistent remembering or "reliving" of the stressor, and (iii) 
avoidance of circumstances resembling or associated with the stressor. In addition, either the 
inability to recall important aspects of the period of exposure to the stressor, or persistent 
symptoms of increased psychological sensitivity and arousal need to be present (WHO 1992). 
To make the diagnosis, these symptoms must persist for more than a month after the occurrence 
of a traumatic event (WHO 1992). Similar criteria are used in the Diagnostic and Statistical 
Manual of Mental Disorders (DSM)-5 to diagnose PTSD, namely the exposure to a traumatic 
event, in addition to having symptoms from each of the four symptom clusters: avoidance, 
intrusion, negative alterations in cognitions and mood, and alterations in arousal and reactivity. 
Furthermore, the functioning of a patient must be impaired and their symptoms should not be 
attributable to substance abuse or a co-occurring medical condition (APA 2013). To establish 
the diagnosis of PTSD, several clinical interviews and questionnaires are available, most of 
which are based on DSM-IV or DSM-5 criteria. Examples of diagnostic instruments related to 
the presented topic are the Clinician-Administered PTSD Scale (CAPS; Blake et al. 1995), the 
PTSD Checklist (PCL; Blanchard et al. 1996; a civilian and military version are also available, 
PCL-C and PCL-M respectively, Weathers et al. 2013), the Structured Clinical Interview for 
DSM Disorders (SCID-I; Spitzer et al. 1992, Ventura et al. 1998), Los Angeles Symptom 
Checklist (LASC; King et al. 1995), the Short Post-Traumatic Stress Disorder Rating Interview 
(SPRINT; Connor & Davidson 2001) and the Posttraumatic Diagnostic Scale (PDS; Foa et al. 
1997, Sheeran & Zimmerman 2002). 
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Traumatic exposure itself is not the only causal factor for PTSD. The type and duration of 
trauma, psychological factors like personality characteristics, gender, and biological factors all 
seem to play a significant role in PTSD aetiology (Yehuda et al. 1995, Breslau et al. 1997, 
Frans et al. 2005). Several mechanisms have been implicated in the pathophysiology of PTSD 
including genetics, epigenetics, and neurobiological systems (Pitman et al. 2012, Bailey et al. 
2013, Ryan et al. 2016). Recently, PTSD research has focused on immune mechanisms, for 
example, peripheral blood mononuclear cells (PBMCs) and cytokines, such as tumor necrosis 
factor - alpha (TNF-; Andrews & Neises 2012). TNF- is an inflammatory, pleiotropic 
cytokine mainly produced by macrophages to aid immune cell regulation (Lebrec et al. 2015). 
Apart from its key immune-regulatory role, it has been associated with several psychiatric 
disorders including depression, schizophrenia, and Alzheimer’s disease (Himmerich et al. 
2008, Lorz et al. 2009, Schmidt et al. 2014, Balõtšev et al. 2016, Decourt et al. 2017). 
Furthermore, research has suggested pro-inflammatory markers, such as TNF-, are potentially 
involved in the development of PTSD (von Känel et al. 2007). TNF- acts via two types of 
TNF receptors (TNF-R), TNF-R p55 and TNF-R p75. TNF- is produced from peripheral 
immune cells and also in the central nervous system, having receptors on the surface of neurons 
and glial cells (Idriss & Naismith 2000). Evidence suggests that the blood-brain barrier is 
permeable to peripherally produced cytokines, including TNF-. Thus, TNF-α can influence 
brain physiology by stimulating the hypothalamic-pituitary-adrenocortical (HPA) axis, 
activating monoamine reuptake and decreasing production of serotonin, due to the increased 
activity of indolamine-2,3-dioxygenase (Lichtblau et al. 2013). 
 
Growing evidence suggests a pathophysiological role of pro-inflammatory cytokines in PTSD. 
As TNF-α is a key cytokine of the immune response (Lebrec et al. 2015), for which blocking 
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drugs are available, we sought to carry out this review of research investigating TNF-α 
concentrations and/or production in human and animal studies of PTSD. The purpose of this 
systematic review is to summarise the evidence regarding the role of TNF- in PTSD, and to 
assess its potential as a biomarker for PTSD and its treatment, in addition to assessing it as a 
potential future drug target. Specifically, we aim to (i) determine whether TNF-α 
concentration/production differs between those with and without PTSD; (ii) assess whether 
TNF-α concentrations change over time and/or in response to treatment; and (iii) explore the 
role of TNF-α in animal models of PTSD. 
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Methods 
This systematic review was conducted following the recommendations outlined in the 
PRISMA guidelines (Moher et al. 2009).  
 
Selection Criteria 
Studies of any design that assessed TNF-α production in-vitro or TNF-α concentration in the 
serum, plasma, or cerebrospinal fluid (in-vivo) of individuals with PTSD were eligible for 
inclusion. Studies were included if they reported a group and/or longitudinal comparison of 
TNF-α concentration/production. Publications reporting on the measurement of TNF-α, the 
TNF-α protein or its messenger ribonucleic acid (mRNA) in animal models of PTSD were also 
included. 
 
Studies were excluded if: (i) they focused on life difficulties or trauma rather than PTSD as 
defined by ICD-10 and DSM-5; (ii) they reported genetic data only; (ii) they measured TNF 
receptors only; (iv) they were investigating glucocorticoid receptor (GR) sensitivity only; or 
(v) they did not report a group and/or longitudinal comparison of TNF-α 
concentration/production. Review articles, meta-analyses, conference proceedings/abstracts, 
editorials, letters, book chapters, and unpublished theses were also not included. 
 
Search Strategy 
Pubmed was searched from inception until the 11th April 2017 using the following key search 
terms: (("post-traumatic stress disorder"[Title/Abstract]) OR ("PTSD"[Title/Abstract])) AND 
(("tumor necrosis factor-alpha"[Title/Abstract]) OR ("tumor necrosis factor"[Title/Abstract]) 
OR ("TNF-alpha"[Title/Abstract]) OR ("TNF"[Title/Abstract])) 
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This search was supplemented by internet searches and hand-searches of reference lists of 
included papers and potentially relevant reviews. Citation tracking in Google Scholar was also 
performed. Identified articles had their titles and abstracts screened according to the pre-
specified eligibility criteria. The eligible articles were further reviewed in full text. The articles 
were subsequently categorized into animal and human studies and then further divided 
according to their study design. An overview of the literature search is shown in Figure 1. 
 
Data Extraction 
The data from all included studies was extracted into an electronic summary table by the first 
author (SM), which was then checked by another author (BD). Information collected related to 
the sample characteristics, study design, and relevant findings.  
 
 
Figure 1 here 
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Results 
Characteristics of included studies 
A total of 27 articles were eligible for inclusion in this review. We identified three articles that 
used animal models of PTSD to assess TNF-α and 24 human studies (including data from a 
total of 1865 participants). The human studies were further categorized into articles with cross-
sectional data using in vivo methods (n=19; including studies measuring serum or plasma 
concentrations of TNF-α, articles with cross-sectional data on TNF-α production in-vitro (n=5), 
or articles with longitudinal data (n=3), two of which considered the effect of treatment 
interventions on TNF-α concentrations. One of the included studies reported both cross-
sectional and longitudinal data (Jergović et al. 2015) and another study provided data on in-
vivo and in-vitro measurements of TNF-α (Gola et al. 2013).  
 
Assessment of PTSD symptoms. Various questionnaires were used for assessment of PTSD 
symptoms in the included studies. Most studies used the CAPS (e.g. von Känel et al. 2007, 
Hammad et al. 2012, Gola et al. 2013, Lindqvist et al. 2014, Bersani et al. 2016, Lindqvist et 
al. 2017, Bruenig et al. 2017). However, other questionnaires, such as the PCL-M (Devoto et 
al. 2016), the PCL-C (Chen et al. 2014), the SCID-I (Bersani et al. 2016; Lindqvist et al. 2017), 
the PDS (Himmerich et al. 2015), and the LASC (Jergović et al. 2015), were also used. Some 
of the studies established the diagnosis clinically based on ICD-10 criteria (Oganesyan et al. 
2009) or DSM-IV (Guo et al. 2012).  
 
Study findings: Animal Studies  
All included animal studies used animal models with male Sprague-Dawley rats. Two of the 
studies measured TNF-α levels (Levkovitz et al. 2015, Liu et al. 2016) and one assessed TNF-
α mRNA (Lee et al. 2016) in the hippocampus of stressed rats. The results of these studies are 
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presented in Table 1. Lee et al. (2016) induced anxiety using a single prolonged stress (SPS) 
procedure and found elevated TNF-α levels in the hippocampus of stressed rats, as compared 
to non-stressed rats. In contrast, stressed rats who received ibuprofen did not display elevated 
TNF-α expression; these levels did not significantly differ from non-stressed rats. In rats 
exposed to the predator scent stress (PSS) paradigm, Levkovitz et al. (2015) also found elevated 
TNF-α levels in the hippocampus, compared to rats not exposed to stress. In addition, in PSS-
exposed rats treated with minocycline (a drug with anti-inflammatory capacities), normalised 
hippocampal TNF-α concentrations were observed. Furthermore, in both of these studies, 
treatment with medication resulted in a reduction in anxiety-like behaviours (as measured by 
the elevated plus maze test) to levels observed in non-stressed rats. Conversely, Liu et al. (2016) 
did not find any difference in TNF-α levels in the hippocampus of rats after SPS compared to 
non-stressed rats.  
 
Table 1 here 
 
Study findings: Human studies 
Cross-sectional studies assessing TNF-α concentrations in-vivo. Nineteen cross-sectional 
studies assessed plasma or serum concentrations of TNF-α in patients with and without PTSD. 
The findings of these studies are presented in Table 2. All included studies compared 
concentrations of TNF-α serum or plasma levels between subjects with and without PTSD, 
with no studies measuring TNF-α in cerebrospinal fluid.  
 
Serum or plasma concentrations of TNF-α were found to be significantly elevated in patients 
with PTSD in 12 of  the included studies (von Känel et al. 2007, Hoge et al. 2009, Oganesyan 
et al. 2009, Vidović et al. 2011, Guo et al. 2012, Hammad et al. 2012, Mkrtchyan et al. 2013, 
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Chen et al. 2014, Lindqvist et al. 2014, Bersani et al. 2016, Devoto et al. 2016, Bruenig et al. 
2017). Lindqvist et al. (2017) only identified this pattern at trend level. Furthermore, for one 
study these results became non-significant when including systolic blood pressure and time 
since trauma as covariates in their analyses (von Känel et al. 2007). The remaining studies 
found no difference in concentrations of TNF-α between those with and without PTSD (Gola 
et al. 2013, Zhou et al. 2014, Himmerich et al. 2015, Jergović et al. 2015, Wang et al. 2016).  
 
Several studies also measured serum or plasma concentrations of other cytokines, including 
the interleukins (IL) IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, and interferon-γ (IFN-γ). Overall, 
results were mixed (see Table 1 for details). A high proportion of studies measuring IL-6 and 
IL-2 identified elevated concentrations of these cytokines in participants with PTSD, compared 
to those without. The majority of studies assessing concentrations of IL-1β, IFN-γ, and IL-10 
reported no differences between those with and without PTSD. Investigations of IL-4 and IL-
8 found contradictory results, observing both elevated and reduced concentrations of these 
cytokines in those with PTSD, in comparison to a control group. Taken together, these results 
suggest an elevation of peripherally produced TNF-α, as well as other pro-inflammatory 
cytokines (IL-6 and IL-2) in patients with PTSD as compared to individuals without PTSD.  
 
Table 2 here 
 
Cross-sectional studies investigating stimulated TNF-α production in-vitro. Five cross-
sectional studies measured stimulated TNF-α production in-vitro comparing individuals with 
and without PTSD (de Kloet et al. 2007, Rohleder et al. 2007, Gill et al. 2008, Gola et al. 2013, 
Jergović et al. 2014). Details regarding the designs and results of these studies are presented in 
Table 3. In Jergović et al. (2014), the effects of PTSD on cytokine production of 
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phytohemagglutinin (PHA) stimulated T cells was investigated. In this study, no difference in 
spontaneous or stimulated TNF-α production between PTSD patients and healthy controls was 
detected. Gola et al. (2013) investigated spontaneous and lipopolysaccharide (LPS)-stimulated 
production of TNF-α in isolated PBMCs. As compared to healthy controls, refugees with PTSD 
spontaneously produced significantly more TNF-α. However, when including smoking as a 
covariate, this difference reduced to trend level only. Furthermore, no group differences were 
observed for stimulated TNF-α production. Rohleder et al. (2004) also found no differences 
between refugees with PTSD and controls in LPS-stimulated production of TNF-α. In contrast, 
de Kloet et al. (2007) found that PTSD patients had reduced production of LPS-stimulated 
TNF-α compared to healthy controls. Gill et al. (2008) measured TNF-α production in PHA 
and LPS-stimulated whole blood, identifying significantly higher TNF-α production in PTSD 
patients as compared to healthy controls and trauma controls (experienced a trauma but did not 
develop PTSD). This was the only study to use exclusively women in their sample. 
Interestingly, both Gola et al. (2013) and Gill et al. (2008) identified positive correlations 
between production of TNF-α (unstimulated only in Gola et al.) and PTSD symptom 
severity/intensity.  
 
Table 3 here 
 
Longitudinal studies. Three longitudinal studies investigating PTSD and TNF-α were identified 
(see Table 4 for further details). Two studies assessed the impact of specific interventions on 
TNF-α in people with PTSD (Gocan et al. 2012, Himmerich et al. 2016), with the remaining 
study measuring TNF-α in combat veterans with chronic PTSD who were receiving treatment-
as-usual (Jergović et al. 2015). Himmerich et al. (2016) assessed German soldiers with PTSD, 
who were randomized to receive either inpatient psychotherapy or outpatient clinical 
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management. It was found that in both treatment groups, serum concentrations of TNF-α 
increased over the six weeks of treatment. These results remained significant when controlling 
for medication. In Gocan et al. (2012), soldiers with treatment-resistant PTSD were required 
to consume a fermented soy formulation (FSWW08) for a 3-month period. In contrast with 
Himmerich et al. (2016), the intervention resulted in a reduction in TNF-α plasma 
concentration. In Jergović et al. (2015) serum TNF-α concentration was measured at baseline 
and after 3 months of treatment-as-usual. No significant differences between these time points 
were observed. However, TNF-α could not be detected in a high percentage of participant’s 
samples.  
 
Table 4 here 
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Discussion  
Summary of Findings 
TNF-α in animal models of PTSD. Elevated levels of TNF-α (mRNA and protein levels) in the 
hippocampus of stressed rats, as compared to non-stressed rats were identified in two of the 
three included animal studies (Levkowitz et al. 2015, Lee et al. 2016). Furthermore, the 
increased levels of TNF-α were not observed in the frontal cortex or hypothalamus (Levkowitz 
et al. 2015). The finding of elevated levels of TNF-α production in the hippocampus of stressed 
rats is very interesting in light of the literature derived from human studies that reports the 
hippocampus to be implicated in PTSD, in terms of both volume and function (e.g. Kitayama 
et al. 2005, Woon et al. 2010, O’Doherty et al. 2015, van Rooij et al. 2015). Taken together, 
these findings suggest a potential pathophysiological role of hippocampal TNF-α production 
in the development of PTSD. Interestingly, when the stressed rats were administered 
medication with anti-inflammatory properties, the elevated TNF-α concentration reduced to 
the level of non-stressed rats (Levkowitz et al. 2015, Lee et al. 2016). Furthermore, this 
coincided with a reduction of anxiety-like behaviours in the treated rats (but not in the stressed 
non-treated rats) which returned to a similar level to that seen in the non-stressed rats. This 
highlights the therapeutic potential that immunomodulatory drugs could have for the treatment 
of PTSD.  
 
TNF-α in human studies of PTSD. In accord with previous reviews and meta-analyses (Passos 
et al. 2015, Wang & Young 2016), concentrations of TNF-α in the plasma and serum of patients 
with PTSD were found to be elevated, as compared to healthy controls. Only one study 
demonstrated a loss of their initial statistical significance when including covariates in the 
analyses (von Känel et al. 2007). It is of note that in two of the remaining studies that found no 
difference in TNF-α concentrations between groups, TNF-α was not detectable in a high 
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percentage of participants (Gola et al. 2013, Jergović et al. 2015), which may account for their 
findings. The results of in-vitro investigations of TNF-α in PTSD were generally inconsistent. 
This is likely due to the heterogeneous methodologies used in these studies, specifically in 
relation to the measurement of TNF-α and the heterogeneity of the sample.  
 
It is of interest to note that concentrations and/or production of TNF-α and other cytokines have 
been shown to be correlated with PTSD symptom severity (von Känel et al. 2007, Gill et al. 
2008, Gola et al. 2013, Dennis et al. 2016). Specifically, concentrations of TNF-α (measured 
using both in-vivo and in-vitro methods) positively correlated with severity/intensity of PTSD 
symptoms (Gill et al. 2008, Gola et al. 2013, Bruenig et al. 2017) and severity and/or frequency 
of specific symptoms, including re-experiencing (Gill et al. 2008) and hyperarousal (von Känel 
et al. 2007, Gill et al. 2008). In von Känel et al. (2007), after including covariates in the 
analyses, the association only remained with hyperarousal symptoms. Given the many possible 
symptom combinations that are presented by individuals with PTSD (Galatzer-Levy & Bryant 
2013), future research needs to consider whether inflammation is only associated with certain 
symptoms (O’Donovan 2016). 
 
An increase of the production of pro-inflammatory cytokines, like TNF-α, has been found in a 
number of studies in which hyperproduction of TNF-α was induced by acute and chronic stress 
paradigms (Cosen-Binker et al. 2004, Binker et al. 2010, Liu et al. 2012, Vorhees et al. 2013). 
More specifically, animal studies with rats have shown that TNF-α plasma concentration 
increased during acute and chronic (Himmerich et al. 2013), as well as social stress (Krügel et 
al. 2014). However, the mechanism as to how stress leads to an increase of pro-inflammatory 
cytokine production is still unclear. There is evidence from the literature for several pathways 
by which TNF-α and other cytokines might have an effect on the brain (Quan 2008). They have 
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been shown to be able to activate the HPA axis, to activate neuronal serotonin transporters, to 
stimulate the indoleamine 2,3-dioxygenase, to contribute to the destruction of neurons, and/or 
to release glutamate (Zhu et al. 2006, Wichers & Maes 2002, Himmerich et al. 2009, Curran & 
O’Connor 2001). Therefore, stress, by inducing an increased production of pro-inflammatory 
cytokines, might trigger neurobiological changes, which could, as a consequence, induce 
psychiatric disorders such as PTSD and depression. 
 
Taken together, it could be suggested that elevated concentrations of TNF-α could be a 
biomarker of PTSD. It is important to consider that TNF-α may not a specific biomarker for 
PTSD, but rather a general marker of psychopathology. Elevated levels of TNF-α have also 
been observed in other psychiatric disorders, including depression (Himmerich et al. 2008, 
Schmidt et al. 2014). Furthermore, given that TNF-α is part of a complex network of cytokines, 
which have also been shown to be elevated in PTSD and other disorders (e.g. Guo et al. 2012, 
Hammad et al. 2012, Schmidt et al. 2014, Bersani et al 2016), a combination of several 
cytokines may be the best indicator. 
 
The data derived from longitudinal studies is difficult to interpret given the mixed findings. 
One study that assessed the effect of inpatient psychotherapy and clinical management found 
an increase in TNF-α concentration over 6 weeks of treatment (Himmerich et al. 2016). In 
contrast, daily consumption of a fermented soy formulation resulted in a decrease in TNF-α 
concentrations over the 3 month intervention (Gocan et al. 2012). However, these studies had 
small samples and did not include a control group. Therefore, it is unclear whether the 
participants with PTSD had elevated concentrations of TNF-α in comparison to healthy 
controls, prior to starting the intervention. Furthermore, the heterogeneity in treatment 
interventions means that they are not directly comparable. Interestingly, both interventions 
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were shown to reduce participant’s scores on PTSD symptom measures. This suggests that 
TNF-α could potentially serve as a state marker of PTSD, given the changes in concentrations 
observed in response to different interventions. An additional longitudinal study found no 
difference in TNF-α concentrations between baseline assessment and after 3 months of 
treatment-as-usual (Jergović et al. 2015). However, in this study TNF-α were not detected in a 
high percentage of participants, so conclusions cannot be drawn. As can be seen, there is limited 
data on longitudinal TNF-α concentrations in treatment studies of PTSD. Therefore, future 
research would benefit from measuring TNF-α over the treatment course to gain a clearer 
understanding of how TNF-α is related to treatment response. Prospective studies would also 
be of benefit, given not everyone who is exposed to a traumatic event will go on to develop 
PTSD (Keane et al. 2009). This may be best suited to a military setting in which cytokines 
could be measured prior to and after deployment with additional follow-up assessments. This 
will help to elucidate the role of cytokines in PTSD and to determine whether elevated TNF-α 
is a state or trait marker of PTSD. 
 
Methodological considerations 
The findings emerging from this review must be interpreted with caution and in light of several 
methodological considerations. Firstly, the human studies presented here used a range of 
assessments to diagnose and/or measure PTSD symptomology. Assessment measures vary 
considerably on factors such as number of items, response format (i.e. self-report vs. 
interview), and the anchoring of the measure (i.e. is it anchored to a specific traumatic event, 
broader stressful experiences, or stressful military experience). With regards to PTSD symptom 
severity, this may make comparing the findings of studies difficult.  
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Secondly, while some studies age-matched participants and controlled for certain covariates in 
their analyses, the majority of the included studies did not account for pre-analytical factors 
that may affect the concentration of certain cytokines. These include factors such as age, BMI, 
smoking, medication, and concurrent diagnoses relating to physical and mental health (Dugué 
et al. 1994). Several studies within this review highlight the importance of this practice, finding 
that previously significant results became non-significant when covarying for certain factors in 
their analyses (e.g. systolic blood pressure: von Känel et al. 2007; smoking: Gola et al. 2013). 
Furthermore, recent meta-analyses have shown that TNF-α was found to be elevated in those 
with PTSD as compared to controls, but only when participants with comorbid depression or 
participants who were on medication were excluded from analyses (Passos et al. 2015, 
O’Donavon 2016). Thus, future studies need to carefully consider factors that may influence 
the measurement of cytokine concentrations and account for them within their study design 
and analyses. 
 
Thirdly, the specific methodologies used to measure cytokine concentrations and production 
varies considerably between studies. These include using different sample types (e.g. for in-
vivo: plasma, serum; for in-vitro: PBMCs, whole blood) and different equipment for measuring 
cytokine concentrations (e.g. ELISA, multiplex arrays). This is problematic as different 
methodologies may yield different results (see Zhou et al. 2015 for a review on methodological 
issues affecting cytokine measurement). For example, research has shown that concentrations 
of cytokines significantly differ between plasma and serum samples (Guo et al. 2013). As a 
result, the findings from these studies may not be directly comparable. 
 
Finally, the majority of the samples in the included studies have small samples and participants 
are limited to males and to those suffering from PTSD due to war i.e. veterans and refugees. 
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Therefore, we cannot be sure that the presented findings will apply to those experiencing PTSD 
due to being exposed to a different trauma e.g. accident, natural disasters, terrorist attacks 
(Wang & Young 2016). Also, some studies used a trauma control group (i.e. they were exposed 
to trauma but did not go on to develop PTSD; e.g. von Känel et al. 2007, Bruenig et al. 2017) 
as opposed to healthy control group (i.e. no experience of trauma). At this point, it is unclear 
as to what extent trauma exposure can influence inflammatory markers in the long-term, even 
without the development of PTSD (Passos et al. 2015). 
 
Conclusions  
To our knowledge, this is the first systematic review considering the specific role of TNF-α in 
PTSD. The current review indicates that (i) generally serum and plasma concentrations of TNF-
α are elevated in those with PTSD in comparison to those without; thus suggesting that TNF-
α may be a potential biomarker of PTSD and serve as a potential therapeutic target for PTSD 
(Neigh & Ali 2016); (ii) TNF-α production in the hippocampus may be involved in the 
underlying pathophysiology of PTSD; and (iii) in animal models of PTSD, anxiety-like 
behaviour can be altered by immunomodulatory drugs, which highlights the future potential of 
this medication for the treatment of PTSD. However, these findings do need to be interpreted 
in view of methodological issues and the potential for publication bias (Thornton & Lee 2000). 
Longitudinal research is needed to understand the state/trait related nature of TNF-α 
concentrations in PTSD. This will enlighten us to the potential biological mechanisms 
underlying PTSD, which may be responsible for the development and/or maintenance of the 
disorder, elucidate if cytokines concentrations could be a potential marker of treatment 
response, and may provide the basis for further investigations into immunomodulatory 
medication as a treatment for PTSD.  
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Table 1. Summary of animal studies investigating the relationship between TNF-α and PTSD. 
 
Author Animals PTSD Model Measurement of 
TNF-α 
Findings regarding 
TNF-α 
Additional findings/comments 
Lee et al. 2016 Adult male Sprague-
Dawley rats 
SPS Hippocampal mRNA 
expression levels; 
Reverse transcription-
polymerase chain 
reaction 
SPS > control 
 
Group treated with ibuprofen 
(40mg/kg body weight): 
TNF-α - SPS + ibuprofen = 
control; SPS + ibuprofen < SPS 
 
Anxiety index in elevated plus 
maze test - SPS > SPS + 
ibuprofen; SPS + ibuprofen = 
control 
Levkowitz et al. 
2015 
Male Sprague-
Dawley rats (n=99) 
PSS Hippocampal protein 
levels; Multiplexed 
ELISA 
PSS > control In frontal cortex & 
hypothalamus: TNF-α - PSS = 
control 
 
Group treated with minocycline: 
TNF-α - PSS > PSS + 
minocycline 
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IL-1α, IL-6 - PSS > control; PSS 
> PSS + minocycline 
Anxiety-like behaviours (time 
spent in open arms and entries) in 
elevated plus maze test - PSS > 
control; PSS > PSS + 
minocycline; PSS + minocycline 
= control 
Liu et al. 2016 Adult male Sprague-
Dawley rats (n=128) 
SPS Hippocampal 
expressions; ELISA 
SPS = control IL-6 - SPS > control 
IL-1β, IL-10 - SPS = control 
TNF-α = tumor necrosis factor - alpha; SPS = single prolonged stress; mRNA = messenger ribonucleic acid; PSS = predator scent stress; ELISA 
= enzyme-linked immunosorbent assays; mg = milligram; kg = kilogram; IL = interleukin 
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Table 2. Human cross-sectional studies assessing plasma or serum concentrations of TNF-α in-vivo in individuals with and without PTSD. 
Author N Sample PTSD 
Assessment 
Measurement of 
TNF-α 
Findings regarding 
TNF-α 
Additional 
findings/comments 
Bersani et al. 
2016 
 
111 Male combat 
veterans with (n=56; 
n=28 concurrent 
MDD) and without 
(n=55; HC) current 
PTSD  
CAPS and SCID Serum; High 
sensitivity 
multiplexed sandwich 
immunoassay 
PTSD > HC 
 
IL-6 - PTSD > HC 
IL-1β, IFN-γ - PTSD = 
HC 
Total pro-inflammatory 
score (TNF-α, IL-6, IL-
1β, IFN-γ & CRP) - 
PTSD > HC 
 
NB includes participants 
from Lindqvist et al. 
(2014). 
Bruenig et al. 
2017 
299 Male trauma-exposed 
Vietnam War 
veterans with 
(n=159) and without 
PTSD (n=140) 
CAPS-5 Serum; Luminex 100 
Milliplex cytokine 
multiplex bead assay  
PTSD > trauma 
control 
 
In the whole sample 
(but not in PTSD 
group only), TNF-α 
correlated positively 
Groups matched for age. 
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with PTSD symptom 
severity. 
Chen et al. 2014 
 
120 Individuals of Li 
ethnicity with PTSD 
(n=30), individuals 
of Han ethnicity with 
PTSD (n=30), HC of 
Li ethnicity (n=30), 
and HC of Han 
ethnicity (n=30) 
PCL-C  
 
PTSD according 
to DSM-IV 
Serum; ELISA For both ethnicities: 
PTSD > HC 
 
For both ethnicities: IL-
2, IL-6, IL-8 - PTSD > 
HC 
 
Devoto et al. 
2016 
 
63 Active duty 
personnel with a 
history of traumatic 
brain injury (TBI) 
with low (n=35) and 
high (n=28) PTSD 
PCL-M Plasma; Paramagnetic 
bead-based ELISA 
High PTSD > Low 
PTSD 
IL-6 - High PTSD > Low 
PTSD 
IL-10 - High PTSD = 
Low PTSD 
IL-6 & TNF-α - TBI > no 
history of TBI  
Gola et al. 2013 
 
60 Refugees with PTSD 
(n=35; n=27 
CAPS 
 
Plasma; Multiplex 
bead-based assays  
PTSD = HC 
 
Results remained true 
when including sex or 
smoking as a covariate. 
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concurrent MDD) 
and HC (n=25)  
PTSD diagnosis 
according to 
DSM-IV 
74.6% of samples 
were below 
detection limit for 
TNF-α 
 
No difference also 
observed in second 
assessment at one 
week after baseline. 
 
 
IL-6, IL-10 - PTSD = HC 
IL-8 - PTSD < HC 
 
Groups matched for 
ethnicity. 
 
See also Table 3 for in-
vitro cross-sectional data. 
Guo et al. 2012 
 
100 Individuals with and 
(n=50; n=22 males) 
without (n=50; n=25 
males; HC) PTSD  
DSM-IV  Serum; ELISA PTSD > HC 
 
IL-2, IL-4, IL-6, IL-8, 
IL-10 - PTSD > HC 
 
Groups matched for age 
and gender. 
Hammad et al. 
2012 
 
13 Combat veterans 
with PTSD (n=8; n=6 
concurrent MDD) 
and male HC (n=5) 
CAPS-DX Plasma; Human 
cytokine 4-plex panel 
PTSD > HC IL-6, IL-10, IFN-γ - 
PTSD > HC 
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Himmerich et al. 
2015 
 
135 Male German 
soldiers 
PDS Serum; BioPlex 
ProTM human 
cytokine 
immunoassay 
PTSD = no PTSD 
 
No significant 
correlation between 
PDS score and TNF-
α concentrations. 
sTNF-R p55 & p75 - 
PTSD = no PTSD 
 
Controlled for smoking, 
BMI and age. 
 
Hoge et al. 2009 56 Individuals with 
PTSD (n=28) and 
HC (n=28) 
SPRINT 
 
PTSD diagnosis 
according to 
DSM-IV 
Plasma; Millipore 
Beadlytes Human 22-
Plex Multi-Cytokine 
Detection System and 
the Luminex 100 
Total System 
PTSD > HC IL-6, IL-1a, IL-1b, IL-2, 
IL-4, IL- 7, IL-8, IL-10, 
IL12p40 and IL12p70, 
IL-13, IL-15, IP-10 - 
PTSD > HC 
 
Groups matched for 
gender and age. 
Jergović et al. 
2015  
 
101 Male combat 
veterans with PTSD 
(n=69) and male HC 
(n=32) 
LASC  
 
PTSD diagnosis 
according to 
ICD-10 
Serum; Bead-based 
multiplex 
immunoassay 
PTSD = HC 
 
TNF-α not detected 
in 80% of PTSD and 
87% of HC samples 
IL-8 - PTSD < HC 
IFN-γ, IL-1β, IL-2, Il-4, 
IL-6 - PTSD = HC 
 
Groups matched for age. 
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See also Table 4 for 
longitudinal data. 
Lindqvist et al. 
2014 
 
102 Male combat-
exposed veterans 
with PTSD (n=51; 
n=27 concurrent 
MDD) and male 
combat-exposed HC 
(n=51) 
CAPS 
 
PTSD diagnosis 
according to 
DSM-IV 
Serum; High 
sensitivity 
multiplexed sandwich 
immunoassay 
PTSD > HC IL-1β, IL-6, IL-10 - 
PTSD = HC 
IFN-γ - PTSD > HC 
 
Controlled for MDD 
diagnosis, BMI, BDI 
score, ETI score, use of 
antidepressants, anti-
inflammatories and 
statins, asthma/allergy 
illnesses, ethnicity, years 
of education, and time 
since combat. 
 
Groups matched for age. 
Lindqvist et al. 
2017 
 
61 Male combat-
exposed veterans 
with PTSD (n=31; 
CAPS 
 
Serum; High 
sensitivity 
PTSD > HC (trend 
only) 
Total pro-inflammatory 
score, IL-6 - PTSD > HC 
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n=20 concurrent 
MDD) and male 
combat-exposed HC 
(n=30) 
PTSD diagnosis 
according to 
DSM-IV 
multiplexed sandwich 
immunoassay 
IFN- γ, IL-10 - PTSD = 
HC 
 
Controlled for age, BMI, 
smoking, medications 
and immune/ 
inflammatory illnesses. 
 
Total pro-inflammatory 
score - PTSD + MDD = 
PTSD no MDD 
 
NB Replication of 
Lindqvist et al. (2014) 
Mkrtchyan et al. 
2013 
 
72 Male war veterans 
with PTSD (n=37) 
and male HC (n=35) 
SCDI-I and 
CAPS 
 
PTSD diagnosis 
according to 
DSM-IV-TR 
Serum; ELISA PTSD > HC  
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Oganesyan et al. 
2009 
 
62 Individuals with 
chronic stage PTSD 
(n=31, n=27 male) 
and HC (n=31, n=27 
male) 
ICD-10 Serum; ELISA PTSD > HC IL-1β, IL-6 - PTSD > HC 
Vidović et al. 
2011 
 
64 Male Croatian 
combat veterans 
(n=39) and male HC 
(n=25) 
CAPS 
 
PTSD diagnosis 
according to 
ICD-10 
Serum; ELISA PTSD > HC 
 
Results collected at 
second assessment 
(average 5.6 years 
after baseline): 
PTSD = HC 
IL-6 - PTSD = HC 
 
 
von Känel et al. 
2007 
28 Individuals with 
PTSD (n=14; n=9 
male) and trauma 
control (n=14; n=9 
male) 
CAPS (German 
Version) 
 
PTSD diagnosis 
according to 
DSM-IV 
Plasma; Ultra-
sensitive enzyme-
linked 
immunosorbent assay 
PTSD > trauma 
control 
 
TNF-α correlated 
negatively with 
systolic BP, and 
positively with time 
since trauma. TNF-α 
Results become 
insignificant when 
controlling for systolic 
BP and time since 
trauma. 
 
IL-1β (controlling for 
anxiety & depression), 
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positively correlated 
with re-
experiencing, 
avoidance, 
hyperarousal, and 
total PTSD symptom 
score, association 
became non-
significant when 
adjusting for systolic 
BP and time since 
trauma (for all 
except 
hyperarousal). 
IL-6, IL-10 - PTSD = 
trauma control 
IL-4 (controlling for 
systolic BP & smoking 
status) - PTSD < trauma 
control 
 
Groups matched for 
gender and age. 
 
Trauma control: All had 
experienced traumatic 
accident but did not 
develop PTSD. 
Wang et al. 2016 13 OEF/OIF Veterans 
with (n=7; n=4 
concurrent MDD) 
and with without 
(n=6) PTSD 
CAPS Plasma; Human 
cytometric bead array 
flex sets 
PTSD = no PTSD IL-2, IFN-γ, IL-6, IL-17 - 
PTSD > no PTSD 
IL-4 - PTSD < no PTSD 
IL-10 - PTSD = no PTSD 
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Zhou et al. 2014 72 Combat veterans 
with PTSD (n=30, 
n=27 male) and HC 
(n=42) 
CAPS and PCL-
M 
Plasma; Bio-Plex 
Luminex 100 system 
PTSD = HC IFN-γ, IL-17 - PTSD > 
HC 
IL-1β, IL-1RA, IL-2, IL-
4, IL-5, IL-6, IL-7, IL-8, 
IL-9, IL-10, IL-12(p70), 
IL-13, IL-15 - PTSD = 
HC 
 
Groups matched for age. 
TNF-α = tumor necrosis factor - alpha; PTSD = post-traumatic stress disorder; ELISA = enzyme-linked immunosorbent assays; IL = interleukin; 
IFN = interferon; MDD = major depressive disorder; OEF/OIF = Operation Enduring Freedom/Operation Iraqi Freedom; HC = healthy control; 
CAPS = Clinician- Administered PTSD scale; PCL-C = PTSD Checklist - Civilian Version; PCL-M = PTSD Checklist - Military Version; 
SCID-I = Structured Clinical Interview for DSM Disorders; LASC = Los Angeles Symptom Checklist; SPRINT = Short Post-Traumatic Stress 
Disorder Rating Interview; PDS = Posttraumatic Diagnostic Scale; BP = blood pressure; CRP = C-reactive protein; BDI = Beck Depression 
Inventory; ETI = Early Trauma Inventory; BMI = body mass index. 
 
 
 
 
 
 
 43 
 
 
 
Table 3. Human cross-sectional studies assessing TNF-α production in-vitro in individuals with and without PTSD. 
Author N Sample PTSD 
Assessment 
Measurement of 
TNF-α 
Findings regarding 
TNF-α 
Additional 
findings/comments 
de Kloet et al. 
2007 
83 Male veterans with 
PTSD (n=29; n=14 
concurrent MDD), 
male trauma control 
(n=29; veterans 
without PTSD) and 
male HC (n=25) 
CAPS Whole blood; NR 
 
Stimuli: LPS 
PTSD < HC 
PTSD = trauma 
control 
Trauma control = 
HC 
 
PTSD with MDD = 
PTSD without MDD 
 
IL-10 - PTSD = HC = 
trauma control 
 
Groups matched on age, 
region and year of 
deployment. 
Gill et al. 2008 76 Females with PTSD 
(n=26; n=13 
concurrent MDD), 
female trauma 
controls (n=29; past 
trauma but no 
PTSD), and female 
CAPS Whole blood; ELISA 
 
Stimuli: PHA plus 
LPS 
PTSD > trauma 
control 
PTSD > HC 
Trauma control = 
HC 
 
IL-6 - PTSD > trauma 
control; PTSD > HC 
IL-1β - PTSD = HC = 
trauma control 
 
Controlled for age, BMI 
and smoking. 
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HC (n=21; no past 
trauma and no PTSD) 
PTSD with MDD > 
PTSD without MDD 
(trend only) 
 
TNF-α positively 
correlated with 
PTSD symptom 
intensity, re-
experiencing 
symptoms, 
hyperarousal 
symptoms, & 
intensity of 
depression. 
Gola et al. 2013 
 
34 Refugees with PTSD 
(n=16) and HC 
(n=18) 
 
In total sample, see 
Table 2: N=27 PTSD 
CAPS 
 
PTSD diagnosis 
according to 
DSM-IV 
PBMCs; Multiplex 
bead-based assays  
 
Stimuli: LPS or 
unstimulated 
Unstimulated: PTSD 
> HC 
 
LPS-stimulated: 
PTSD = HC 
 
Unstimulated TNF-α 
results reduced to trend 
level when smoking 
included as a covariate. 
LPS-stimulated results 
remained true when 
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patients met DSM-IV 
criteria for MDD 
  
Unstimulated TNF-α 
production positively 
correlated with 
PTSD symptom 
severity. 
 
including sex or smoking 
as a covariate. 
 
Unstimulated: IL-1β, IL-
6 - PTSD > HC 
LPS-stimulated: IL-1β - 
PTSD = HC; IL-6 - 
PTSD > HC 
 
Groups matched on 
ethnicity. 
See also Table 2 for in-
vivo cross-sectional data 
Jergović et al. 
2014  
 
101 Male combat 
veterans with PTSD 
(n=30; n=24 
concurrent MDD) 
and male HC (n=17) 
CAPS 
 
PTSD diagnosis 
according to 
ICD-10 
PBMCs; NR 
 
Stimuli: LPS or 
unstimulated 
PTSD = HC Stimulated: IFN-γ, IL-2, 
IL-4 - PTSD=HC 
Unstimulated: IL-4 - 
PTSD = HC; IFN-γ, IL-2 
- PTSD < HC 
 
 46 
 
Telomere length - PTSD 
< HC 
Groups matched on age. 
Rohleder et al. 
2004 
25 Bosnian refugees 
with PTSD (n=12, 
n=7 males; n=2 
concurrent MDD) 
and HC (n=13, n=5 
males) 
SCL-90R and 
HTQ 
 
PTSD diagnosis 
according to 
DSM-IV 
Whole blood; ELISA 
 
Stimuli: LPS 
PTSD = HC IL-6 - PTSD > HC 
 
Groups matched for age 
and gender. 
TNF-α = tumor necrosis factor - alpha; PTSD = post-traumatic stress disorder; ELISA = enzyme-linked immunosorbent assays; IL = interleukin; 
IFN = interferon; MDD = major depressive disorder; HC = healthy control; NR = not reported; CAPS = Clinician- Administered PTSD scale; 
BMI = body mass index; HTQ = Harvard Trauma Questionnaire; SCL-90R = Symptom Checkist-90-Revised; PBMC = peripheral blood 
mononuclear cell; LPS = lipopolysaccharide; PHA = phytohaemagglutinin. 
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Table 4. Human longitudinal studies assessing TNF-α concentration in individuals with PTSD. 
Author N Sample Intervention PTSD 
Assessment 
Measurement of 
TNF-α 
Findings 
regarding TNF-α 
Additional 
findings/comments 
Gocan et al. 2012 10 Male treatment-
resistant soldiers 
with combat-
related PTSD 
Consumption of 
a fermented soy 
formulation: 
FSWW08 
(120ml daily) 
CAPS 
 
PTSD diagnosis 
according to 
ICD-10 
Plasma; ELISA 
 
At baseline (T0) 
and after 
intervention (3 
months; T1) 
T0 > T1 IL-1β, IFN-γ - T0 
> T1 
IL-6 - T0 = T1 
 
CAPS score - T0 > 
T1 
Himmerich et al. 
2016 
38 Male German 
soldiers with 
PTSD 
 
NB recruited from 
Himmerich et al. 
(2015, 2016) - See 
Table 1 
Randomised to 
receive 
immediate 
inpatient 
psychotherapy 
(n=21) or 
outpatient 
clinical 
management 
control group 
(n=17) 
PDS Serum; Bio-Plex 
Pro™ human 
cytokine 
immunoassay 
 
At baseline (T0) 
and after 
treatment (six 
weeks; T1) 
T0 < T1 
 
No correlations 
between change 
in PDS score and 
change in TNF-α 
sTNF-R p55, 
sTNF-R p75 - T0 
> T1 
 
PDS score - T0 > 
T1 
 
Results remained 
significant when 
controlling for 
medication. 
Jergović et al. 
2015 
 
69 Male Croatian 
combat veterans 
with PTSD 
N/A TAU LASC  
 
PTSD diagnosis 
according to 
ICD-10 
Serum; Bead-
based multiplex 
immunoassay 
 
T0 = T1 
 
TNF-α not 
detected in high 
percentage of 
participants 
See Table 2 for in-
vivo cross-
sectional data. 
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TNF-α = tumor necrosis factor - alpha; PTSD = post-traumatic stress disorder; ELISA = enzyme-linked immunosorbent assays; IL = interleukin; 
IFN = interferon; CAPS = Clinician- Administered PTSD scale; LASC = Los Angeles Symptom Checklist; PDS = Posttraumatic Diagnostic 
Scale; sTNF-R = soluble tumor necrosis receptor; T0 = baseline time point; T1 = first time point; N/A = not applicable; TAU = treatment-as-
usual. 
 
 
 
 
At baseline (T0) 
and after 3 
months (T1) 
